AC Immune (ACIU) Capital Expenditures Growth (1y) (2016 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 227.76% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.57% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 143.40% |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -30.31% |
| Sep 30, 2025 | 62.83% |
| Jun 30, 2025 | -499.17% |
| Mar 31, 2025 | -41.14% |
| Dec 31, 2024 | 45.10% |
| Sep 30, 2024 | 38.47% |
| Jun 30, 2024 | 56.38% |
| Mar 31, 2024 | -31.93% |
| Dec 31, 2023 | -107.40% |
| Sep 30, 2023 | -153.01% |
| Jun 30, 2023 | 69.08% |
| Mar 31, 2023 | 63.02% |
| Dec 31, 2022 | -48.71% |
| Sep 30, 2022 | 76.76% |
| Jun 30, 2022 | 19.04% |
| Mar 31, 2022 | 33.08% |
| Dec 31, 2021 | 75.34% |
| Sep 30, 2021 | -98.50% |
| Jun 30, 2021 | -76.96% |
| Mar 31, 2021 | -298.67% |
| Dec 31, 2020 | 187.22% |
| Sep 30, 2020 | -158.55% |
| Jun 30, 2020 | -128.67% |
| Mar 31, 2020 | 57.28% |
| Dec 31, 2019 | -192.15% |
| Sep 30, 2019 | 428.31% |
| Jun 30, 2019 | 425.86% |
| Mar 31, 2019 | 54.78% |
| Dec 31, 2018 | -99.81% |
| Sep 30, 2018 | 99.99% |
| Jun 30, 2018 | 55.54% |
| Mar 31, 2018 | -89.54% |
| Dec 31, 2017 | 120,346.87% |
| Sep 30, 2017 | -594,110.72% |
| Jun 30, 2017 | -837.11% |
| Mar 31, 2017 | -183.08% |
| Dec 31, 2016 | 209.79% |